title: Myocardial delayed enhancement using a single dose (0.1 mmol/kg) of gadobenate dimeglumine: contrast resolution versus intraventricular blood and viable myocardium.
abstract: OBJECTIVE
  This study was done to estimate delayed enhancement (DE) contrast resolution of infarcted myocardium (IM) relative to intraventricular blood (IB) and viable myocardium (VM) using gadobenate dimeglumine (Gd-BOPTA).
  
  
  METHODS
  After approval from the Ethics Committee, we retrospectively evaluated 21 consecutive patients (61+/-10 years) with a healed myocardial infarction who underwent 1.5-T magnetic resonance (MR) imaging using an inversion-recovery-prepared turbo gradient-echo sequence 10 minutes after injection of 0.1 mmol/kg of Gd-BOPTA. Signal intensity (SI) was measured in arbitrary units (au) for IM, IB, VM, and outside the patient. Contrast-to-noise ratio (CNR) was calculated for IM to IB and IM to VM. Seven consecutive patients (59+/-6 years) with a healed myocardial infarction studied with similar technique but with 0.1 mmol/kg of gadoterate meglumine (Gd-DOTA) served as the control group. The Mann-Whitney U test was used to compare groups.
  
  
  RESULTS
  Mean SI of IM was 44+/-16 au for Gd-BOPTA and 20+/-6 au for Gd-DOTA (p<0.001), that of IB 35+/-15 au and 14+/-5 au (p=0.016), and that of VM 7+/-3 au and 5+/-2 au (p=0.116), respectively. Mean IM to IB CNR was 10+/-7 for Gd-BOPTA and 8+/-5 for Gd-DOTA (p=0.836), that of IM to VM was 45+/-27 and 18+/-6, respectively (p=0.012).
  
  
  CONCLUSIONS
  Gd-BOPTA at 0.1 mmol/kg produced a higher myocardial DE and an IM to VM CNR than a single dose of Gd-DOTA. No significant difference was observed for IM to IB CNR.
authors.affiliation: Dipartimento di Scienze Medico-Chirurgiche, IRCCS Policlinico San Donato, Servizio di Radiologia, Università degli Studi di Milano, Via Morandi 30, 20097 San Donato Milanese, Milano, Italy.
authors.forename: G D E
authors.initials: GD
authors.lastname: Papini
authors.forename: S
authors.initials: S
authors.lastname: Tritella
authors.forename: F
authors.initials: F
authors.lastname: Secchi
authors.forename: A
authors.initials: A
authors.lastname: Aliprandi
authors.forename: G
authors.initials: G
authors.lastname: Di Leo
authors.forename: F
authors.initials: F
authors.lastname: Sardanelli
mesh_terms: D003287:Contrast Media / Q000008:administration & dosage*; D005260:Female; D006571:Heterocyclic Compounds / Q000008:administration & dosage*; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000473:pathology*; D009942:Organometallic Compounds / Q000008:administration & dosage*; D012189:Retrospective Studies; D018709:Statistics, Nonparametric
chemical_list: D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; C050823:gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate